Ashwin Chetty
@ashwinkchetty
Followers
10
Following
57
Media
0
Statuses
7
MD Student @YaleMed; formerly @CloseConcerns and Yale '21 (he/him/his)
New Haven, CT
Joined November 2024
Approximately 5 million adult #Medicaid beneficiaries risk losing coverage due to HR 1's work requirements, with a substantial portion having chronic conditions, particularly among those aged 50 to 64. https://t.co/YgTIAc7J5d
0
3
11
#Obesity and #overweight significantly contribute to obesity-related conditions in US youth, highlighting the need for effective prevention and treatment strategies. https://t.co/8ieUNJSZZs
@ashwinkchetty
0
1
2
Nearly 17 million US adolescents and young adults are eligible for #GLP1 receptor agonist therapy primarily due to #obesity, with substantial numbers uninsured or lacking regular health care access. https://t.co/RcCmmtCQRl
@ashwinkchetty
0
1
1
Our latest paper in @JAMAHealthForum, led by @ashwinkchetty, examines how compounding pharmacies advertise their GLP-1 drugs (i.e., Ozempic, Wegovy) online. Half the websites did not report adverse effects and safety warnings. More below. 🧵 https://t.co/8YgzTJuGgd
jamanetwork.com
This cross-sectional study evaluates the quality and accuracy of information presented on websites that sell compounded glucagon-like peptide-1 receptor agonists.
1
3
4
Our study shows that websites selling compounded GLP-1s often partially inform and sometimes misinform consumers. We need oversight + clearer guidelines for compounded drug advertising. Had a blast working with @mchillakanti, @reshmagar, @jsross119, and Alissa Chen!
Online marketing for compounded GLP-1 drugs overstates benefits and underplays risks
0
3
3
Half of Medicare beneficiaries with overweight/obesity are ineligible for weight loss drugs. Working with @mihir_khunte was a blast, and I so appreciated the mentorship of Alissa Chen, Yuan Lu, @hmkyale, and @AniaJastreboff. See our work in @JournalGIM:
link.springer.com
Journal of General Internal Medicine -
📚 Check out this article on Medicare beneficiaries' eligibility for weight loss drugs by Solomon Center Student Fellow Ashwin Chetty (@ashwinkchetty) & colleagues!
0
1
3